Valuation : Delcath Systems, Inc.

Market Cap 572M 492M 462M 422M 788M 54.06B 795M 5.46B 2.13B 27.62B 2.15B 2.1B 88.97B P/E 2026 *
-110x
P/E 2027 * -206x
Enterprise Value 572M 492M 462M 422M 788M 54.06B 795M 5.46B 2.13B 27.62B 2.15B 2.1B 88.97B EV / Sales 2026 *
5.38x
EV / Sales 2027 * 4.33x
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
1 day-1.12%
1 week+0.67%
Current month-0.06%
1 month+25.19%
3 months+52.45%
6 months+78.22%
Current year+62.87%
1 week 16.1
Extreme 16.1
16.78
1 month 12.43
Extreme 12.43
17.42
Current year 8.48
Extreme 8.485
17.42
1 year 8.12
Extreme 8.12
17.42
3 years 2.25
Extreme 2.25
18.23
5 years 2.25
Extreme 2.25
18.23
10 years 2.25
Extreme 2.25
525,609,756.1
Manager TitleAgeSince
Chief Executive Officer 62 2020-09-30
Director of Finance/CFO 47 2023-04-30
Chief Operating Officer 55 2024-03-17
Director TitleAgeSince
Chairman 62 2023-02-15
Director/Board Member 70 2020-02-13
Director/Board Member 60 2020-05-05
Date Insider Type Main position Quantity % Market Cap. Importance
5/13/26 Free

Director

22,500 0.0646%
5/13/26 Free

Director

22,500 0.0646%
5/13/26 Free

Director

22,500 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%+0.67%+48.19%+253.75% 572M
-0.44%+1.50%0.00%-30.67% 18.76B
-0.55%+0.43%-0.93%+1.07% 17.39B
+1.26%+4.88%-52.23%-46.72% 6.63B
-1.10%-1.50% - - 4.4B
+3.62%+11.46%+36.99%+81.43% 2.08B
-0.78%-1.70%-10.53%-4.30% 1.92B
-1.36%-2.72%-51.28%-57.45% 1.12B
-0.13%-3.66%+48.50%+145.34% 943M
+0.74%-5.04% - - 293M
Average +0.01%+0.22%+2.34%+42.81% 5.41B
Weighted average by Cap. -0.21%+1.39%-5.87%-9.88%

Financials

2026 *2027 *
Net sales 106M 91.38M 85.76M 78.46M 146M 10.04B 148M 1.01B 395M 5.13B 399M 390M 16.52B 132M 114M 107M 97.5M 182M 12.48B 183M 1.26B 491M 6.38B 496M 485M 20.53B
Net income -5.72M -4.92M -4.62M -4.23M -7.89M -541M -7.95M -54.65M -21.28M -276M -21.48M -21.02M -890M -3.39M -2.92M -2.74M -2.5M -4.67M -320M -4.71M -32.36M -12.6M -164M -12.72M -12.45M -527M
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
156
Date Price Change Volume
26-09-04 US$16.45 -0.18% 6,244
26-09-03 US$16.48 -0.60% 268,647
26-09-02 US$16.58 +1.10% 448,647
26-09-01 US$16.40 -0.36% 360,378
26-08-31 US$16.46 +0.73% 402,690
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
16.48USD
Average target price
24.00USD
Spread / Average Target
+45.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DCTH Stock